


## Electronic Supplementary Material

## A Vesicular Stomatitis Virus-based Vaccine Carrying Zika Virus Capsid Protein Protects Mice from Viral Infection


Xiaodan Shi<sup>1#</sup>, Jingping Hu<sup>1#</sup>, Jing Guo<sup>1</sup>, Chuanjian Wu<sup>1</sup>, Sidong Xiong<sup>1✉</sup>,  
Chunsheng Dong<sup>1✉</sup>

1. Jiangsu Key Laboratory of Infection and Immunity, The Institutes of Biology and Medical Sciences, Soochow University, Suzhou 215123, China

Supporting information to DOI: 10.1007/s12250-019-00083-7



**Fig. S1** Construction and characterization of recombinant VSV-ZikaE260-425 and VSV-Capsid vaccines. **A** Microscopy images of BHK-21 cells infected with VSV-ZikaE260-425 or VSV-Capsid at 24 h post-infection. Non-infected cells were used as mock control, and VSV-GFP-infected cells were used as positive controls. **B**. The growth curves of VSV-GFP, VSV-ZikaE260-425 and VSV-Capsid virus. **C**. Immunofluorescence microscopy analysis of BHK-21 cells infected with VSV-ZikaE260-425 or VSV-Capsid at 10 MOI for 12 h. Flag antibody was used to detect the ZIKV envelope and capsid proteins. Non-infected cells were used as mock controls. Scale bar = 10  $\mu$ m.



**Fig. S2** The relative viral genomic RNA fold change in the blood, spleen, brain, testis, and spinal cord of mice on 0, 2, and 4 days post-infection were measured by real-time PCR. Mice were intraperitoneally injected with  $10^4$  PFU ZIKV PRVABC59. The relative viral RNA level was normalized with GAPDH gene and set the level of mice on 0 day as 1.